Ada Health GmbH, a Berlin, Germany-based digital health company, raised USD90m in Series B funding.
The round was led by Leaps by Bayer, the impact investment arm of Bayer AG, with participation from Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures.
The company intends to use the funds to advance its health assessment technology, as well as to further grow in the United States.
Led by Daniel Nathrath, CEO, Ada Health has developed an AI-based health assessment and care navigation platform to understand their symptoms, to identify and differentiate conditions with medical accuracy, and to navigate safely to the right care, at the right time. The consumer app has completed over 23m assessments completed since its global launch.
The company’s core technology is also available in a suite of AI-driven enterprise solutions. Ada is collaborating with a range of leading health systems, insurers, life sciences companies, and global non-profit organizations to integrate its symptom assessment and care navigation solutions into a range of digital care journeys to improve outcomes for patients, consumers and healthcare providers.